MedPath

Study Intended to Evaluate the Safety and Effectiveness of a Johnson & Johnson Vision Care Inc, (JJVCI) Contact Lens for Use on an Extended-wear Basis for up to 7 Days (6 Nights).

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: galyfilcon A
Device: etafilcon A
Registration Number
NCT00241280
Lead Sponsor
Johnson & Johnson Vision Care, Inc.
Brief Summary

Study in the US intended to evaluate the safety and effectiveness of a Johnson \& Johnson Vision Care Inc, (JJVCI) contact lens for use on an extended-wear basis for up to 7 days (6 nights).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
504
Inclusion Criteria
  • The subject must be at least 18 years of age.
  • The subject must read and sign the statement of informed consent and be provided with a copy of the form.
  • Minimum of 7 days of successful lens wear
  • Contact lens prescription requiring between -1.00 to -6.00 D spherical power
  • Less than 1.00 D of astigmatism in either eye
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Testgalyfilcon Agalyfilcon A contact lens being worn 7 days/6 nights.
Controletafilcon Aetafilcon A contact lens being worn 7 days/6 nights.
Primary Outcome Measures
NameTimeMethod
Rate of Contact Lens Related Serious and Significant Events (SSE)Throughout the duration of the study (1 Year)

The number of Contact-Lens related Serious and Significant Adverse Events were reported for each study lens. The incidence of rates of contact-lens related SSEs were calculated as (# of subjects that experienced an event)/(total # subjects). If there were multiple diagnostic findings, the event was categorized under the highest event level diagnostic.

Monocular Contact Lens Snellen Visual Acuity Worse Than 20/40Follow-up Visits- 24 hr, 1, 4, 12, 24,36, and 52 weeks

Percentage of subject eyes reported with visual acuity worse than 20/40 at each study visit.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (25)

Cole, Cole, and Krohn

🇺🇸

Fresno, California, United States

Fukai and Associates

🇺🇸

Louisville, Colorado, United States

Peter C. Donshik, MD

🇺🇸

Bloomfield, Connecticut, United States

Scott Jens, OD

🇺🇸

Middleton, Wisconsin, United States

Steven S. Grant, OD

🇺🇸

Costa Mesa, California, United States

Kenneth A. Young, OD

🇺🇸

Brentwood, Tennessee, United States

Kenji Hamada, OD

🇺🇸

Grants Pass, Oregon, United States

Drs. Quinn, Quinn and Associates

🇺🇸

Athens, Ohio, United States

InSight Eyecare

🇺🇸

Warrensburg, Missouri, United States

First Eye Care Plano

🇺🇸

Plano, Texas, United States

Jack J. Yager, OD

🇺🇸

Orlando, Florida, United States

Central Ohio Eyecare

🇺🇸

Columbus, Ohio, United States

Clayton Eye Center

🇺🇸

Morrow, Georgia, United States

Eyecare Associates

🇺🇸

Bloomington, Illinois, United States

Charles Wegman, OD

🇺🇸

Carrollton, Texas, United States

Drs. Hawks, Besler & Rogers

🇺🇸

Gardner, Kansas, United States

Snowy Range Vision Center

🇺🇸

Laramie, Wyoming, United States

Gary W. Jerkins, MD

🇺🇸

Nashville, Tennessee, United States

Dr. William Bogus

🇺🇸

Salt Lake City, Utah, United States

West Hills Vision Center

🇺🇸

Moon Township, Pennsylvania, United States

Wishnow-Sugar Vision Group

🇺🇸

Katy, Texas, United States

Dr. Ted Brink and Associates

🇺🇸

Jacksonville, Florida, United States

Univ Missouri at St. Louis, College of Optometry

🇺🇸

St. Louis, Missouri, United States

Premier Vision

🇺🇸

Amarillo, Texas, United States

Lee Rigel

🇺🇸

East Lansing, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath